NURIX THERAPEUTICS IN

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

25 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

20 мар 2024 08:40:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

11 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

06 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

05 мар 2024 15:30:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

15 фев 2024 15:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

01 фев 2024 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

16 янв 2024 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

08 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

11 дек 2023 11:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

04 дек 2023 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

07 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

02 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

01 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

12 окт 2023 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

07 сен 2023 06:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 авг 2023 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

13 июл 2023 15:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

14 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire